Can Ustekinumab be covered by medical insurance?

The original drug Ustekinumab (Ustekinumab) has been marketed in China. It is available in two forms: subcutaneous injection preparations and intravenous infusion preparations. Currently, it has passed the relevant regulations of the National Medical Insurance Bureau and is covered by Class B medical insurance reimbursement, but it is only reimbursed for patients who meet the indications. Reimbursement for intravenous ustekinumab is limited to adults with moderately to severely active Crohn's disease who have had an inadequate response to, failed to respond to, or are intolerant to conventional treatments or tumor necrosis factor a (TNF-a) antagonists.

The reimbursement conditions for subcutaneous ustekinumab are limited to adult patients with moderate to severe plaque psoriasis who are unresponsive, contraindicated or intolerant to other systemic treatments such as cyclosporine, methotrexate (MTX) or PUVA (psoralen and ultraviolet A); or to other systemic treatments. Children and adolescents aged 6 years and older (weight 60 kg to 100 kg) with moderate to severe plaque psoriasis who have an inadequate response to, or are intolerant to, conventional treatments or phototherapy; or adult patients with moderate to severe active Crohn's disease who have an inadequate response to, have no response to, or are intolerant to conventional treatments or tumor necrosis factor a (TNFa) antagonists.

Ustekinumab antigenic drug sold in China, specificationsThe price of 130mg/26ml intravenous injection preparation may be more than 5,000 yuan per box, and the price of 90mg: 1.0ml*1 subcutaneous injection preparation may be more than 8,000 yuan per box. The price of the 130mg/26ml intravenous injection preparation of Ustekinumab sold overseas may be more than 2,000 US dollars per box, and the price of 45mg: 0.5ml*1 subcutaneous injection preparation per box may be more than 10,000 US dollars. There are currently no generic versions of ustekinumab produced in other overseas countries.